Child cancer drug approved for NHS use

60% of children with high-risk neuroblastoma can be treated with dinutuximab beta Related items fromOnMedica One in 10 children in phase I cancer trials respond to drugs Children need access to cancer drug ‘goldmine’ NICE rejects adjuvant use of breast cancer drug New breast cancer drug ‘unaffordable’ for NHS Drug could double head and neck cancer survival
Source: OnMedica Latest News - Category: UK Health Source Type: news

Related Links:

Publication date: Available online 16 October 2019Source: Diagnostic and Interventional ImagingAuthor(s): E.M. Weisberg, L.C. Chu, S. Park, A.L. Yuille, K.W. Kinzler, B. Vogelstein, E.K. Fishman
Source: Diagnostic and Interventional Imaging - Category: Radiology Source Type: research
Publication date: Available online 17 October 2019Source: European Journal of RadiologyAuthor(s): Said Pertuz, Antti Sassi, Kirsi Holli-Helenius, Joni Kamarainen, Irina Rinta-Kiikka, Anna-Leena Laaperi, Otso ArponenAbstractPurposeTo assess the association between breast cancer risk and mammographic parenchymal measures obtained using a fully-automated, publicly available software, OpenBreast.MethodsThis retrospective case-control study involved screening mammograms of asymptomatic women diagnosed with breast cancer between 2016 and 2017. The 114 cases were matched with corresponding healthy controls by birth and screening ...
Source: European Journal of Radiology - Category: Radiology Source Type: research
ConclusionsThese results suggest that compared with PI-RADS v2, PI-RADS v2.1 could be preferable for evaluating TZ lesions.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Conclusion: Standardized evaluation of TIL levels may provide valuable prognostic information in a spectrum of different malignancies. PMID: 31621387 [PubMed - as supplied by publisher]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Conclusion MTDH is pro-oncogenic factor playing multifaceted and diverse roles in cancer progression. Its association and central role in regulating signaling pathways such a MAPK, wnt/β-catenin, PI3K/AkT, NF-κβ pathways in various cancers shows that it plays a vital role in metastasis. MTDH contribution to chemo and radiotherapy resistance provides a new direction for the development of anticancer therapeutics. Multiple mechanisms converge to promote expression of MTDH in cancers. Further studies are therefore warranted to determine whether the elevated MTDH expression has prognostic value for development...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: These new findings indicated that the CCL2/CCR2 axis promoted the progression of SACC cells via recruiting and reprogramming TAMs. Targeting TAMs by blocking the CCL2/CCR2 axis might be a prospective strategy for SACC therapy. Introduction Salivary adenoid cystic carcinoma (SACC) is one of the most commonly diagnosed salivary gland malignancies, accounting for about 10% of all salivary gland neoplasms (1, 2). The typical characteristics of SACC include the recurrent growth, aggressive invasion, hematogenous metastasis, and chemotherapy refractory (2–4). Despite the great efforts paid in the treatm...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In Reply We thank Drs Kim and Budhram for their valuable suggestion. Owing to the 600-word limit in the Observation section, much of the information associated with this patient had to be omitted in the article. Herein we fill in some of the gaps. We agree that magnetic resonance imaging is the first priority for excluding a paraneoplastic or parainfectious origin when treating a patient with opsoclonus. Small cell carcinoma of the lung, breast cancer, and ovarian cancer are most prevelent in adults with opsoclonus, whereas neuroblastoma accounts for more than 50% prevalence in children. Of course, such work-up had been do...
Source: JAMA Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Source Type: research
Authors: Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, Parikh A, Pasquier E, Patil V, Prabhash K, Shaked Y, Sholler GS, Sterba J, Waxman DJ, Banavali S Abstract The 5(th) Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6(th) - 8(th) May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including m...
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
Montalto G, Cervello M, Milella M, Tafuri A, Demidenko Z, Abrams SL, McCubrey JA Abstract The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be diff...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Children | Head and Neck Cancer | National Institute for Health and Clinical Excelle | Neuroblastoma | Neurology | UK Health